Rhythm Pharmaceuticals, Inc. (RYTM)
Largest Insider Buys in Sector
RYTM Stock Price History Chart
RYTM Stock Performance
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC …
Insider Activity of Rhythm Pharmaceuticals, Inc.
Over the last 12 months, insiders at Rhythm Pharmaceuticals, Inc. have bought $0 and sold $24.65M worth of Rhythm Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rhythm Pharmaceuticals, Inc. have bought $201,713 and sold $18.62M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $201,713 was made by Meeker David P (President and CEO) on 2021‑03‑30.
List of Insider Buy and Sell Transactions, Rhythm Pharmaceuticals, Inc.
| 2024-09-17 | Sale | director | 31,751 0.0512% | $52.40 | $1.66M | -5.35% | ||
| 2024-09-10 | Sale | director | 17,501 0.029% | $49.65 | $868,923 | +2.29% | ||
| 2024-09-09 | Sale | Chief Human Resources Officer | 4,099 0.0066% | $50.03 | $205,062 | -0.93% | ||
| 2024-09-09 | Sale | director | 3,199 0.0052% | $50.04 | $160,068 | -0.93% | ||
| 2024-09-09 | Sale | director | 37,241 0.0607% | $50.45 | $1.88M | -0.93% | ||
| 2024-08-26 | Sale | Chief Human Resources Officer | 3,200 0.0052% | $50.01 | $160,018 | -0.84% | ||
| 2024-08-26 | Sale | director | 4,300 0.007% | $50.01 | $215,029 | -0.84% | ||
| 2024-08-26 | Sale | director | 14,508 0.0237% | $50.01 | $725,526 | -0.84% | ||
| 2024-08-12 | Sale | director | 10,000 0.0165% | $44.65 | $446,462 | +11.35% | ||
| 2024-08-09 | Sale | Chief Human Resources Officer | 49,006 0.08% | $45.15 | $2.21M | +9.41% | ||
| 2024-07-29 | Sale | Chief Human Resources Officer | 1,395 0.0023% | $49.06 | $68,439 | +0.64% | ||
| 2024-07-16 | Sale | Chief Technical Officer | 10,468 0.0228% | $53.00 | $554,817 | -8.61% | ||
| 2024-07-12 | Sale | Chief Technical Officer | 5,313 0.0109% | $50.01 | $265,725 | 0.00% | ||
| 2024-05-09 | Sale | Chief Technical Officer | 3,984 0.0065% | $38.47 | $153,259 | +21.82% | ||
| 2024-04-02 | Sale | Corporate Controller & CAO | 368 0.0006% | $41.76 | $15,368 | +9.96% | ||
| 2024-03-21 | Sale | Chief Technical Officer | 18,235 0.0301% | $40.34 | $735,600 | +7.52% | ||
| 2024-03-20 | Sale | EVP, Head of North America | 18,235 0.0296% | $38.77 | $707,005 | +9.90% | ||
| 2024-03-19 | Sale | President and CEO | 45,494 0.0758% | $39.22 | $1.78M | +11.41% | ||
| 2024-03-19 | Sale | Chief Financial Officer | 15,515 0.0259% | $39.22 | $608,498 | +11.41% | ||
| 2024-03-19 | Sale | Chief Human Resources Officer | 15,515 0.0259% | $39.22 | $608,498 | +11.41% |
Insider Historical Profitability
| Meeker David P | President and CEO | 174605 0.2856% | $62.98 | 2 | 2 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4909956 8.0315% | $62.98 | 1 | 0 | +9.57% |
| BARRETT M JAMES | 10 percent owner | 4909956 8.0315% | $62.98 | 1 | 0 | +9.57% |
| MOTT DAVID M | 10 percent owner | 4909956 8.0315% | $62.98 | 1 | 0 | +9.57% |
| KERINS PATRICK J | 10 percent owner | 4909956 8.0315% | $62.98 | 1 | 0 | +9.57% |
Institutional Investor Ownership
| PRIMECAP Management Co | $335.7M | 12.71 | 7.75M | -3.79% | -$13.22M | 0.25 | |
| BlackRock | $282.93M | 10.71 | 6.53M | +2.8% | +$7.71M | 0.01 | |
| Baker Bros Advisors LP | $277.24M | 10.49 | 6.4M | 0% | +$0 | 1.99 | |
| RA Capital Management, L.P. | $230.97M | 8.74 | 5.33M | 0% | +$0 | 0.23 | |
| Goldman Sachs | $221.49M | 8.38 | 5.11M | +1.26% | +$2.76M | 0.04 |